Close Menu


A data safety monitoring committee said the trial, exploring the first-line activity of bintrafusp against Keytruda in PD-L1-high, advanced NSCLC, wouldn't meet its primary endpoint.

Drugmakers discussed advancing autologous CAR T-cell therapeutic programs, and several diagnostic firms detailed their efforts in precision oncology. 

A recent paper details how, across several cancer types, high TMB is associated with improved outcomes with immunotherapy but worse outcomes without it.

Although a record number of new precision oncology drugs came to market, the pandemic further exposed access gaps that the field is focused on mitigating.

Although the pandemic may have been at the forefront of readers' minds, they remained interested in the latest advances and controversies in precision oncology.

The Phase III Keynote-775 study has shown that the combination improves overall and progression-free survival compared to chemotherapy.

The European Commission will review CHMP's opinion based on the Keynote-177 data and is expected to issue a final decision in the first quarter of 2021.

The B44 supertype is associated with improved survival in melanoma patients treated with immunotherapy, but less so in NSCLC patients, due to mutational differences.

The agency approved Agilent/Dako's PD-L1 IHC test for identifying TNBC patients who are most likely to respond to Keytruda and chemo.

In the wake of encouraging interim results, Moderna plans to expand the head and neck cancer cohort of its mRNA-4157 plus Keytruda clinical trial.